Drugs / sNN0031
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01829867 | Apr 2013 → Oct 2015 | Parkinson disease | Newron Sweden AB | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00866502 | Mar 2009 → Mar 2011 | Parkinson disease | Newron Sweden AB | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-01-14 | Newron Pharmaceuticals SPA | Newron initiates Phase II study of sNN0031 in patients with Parkinson’s disease newron.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sNN0031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01829867 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human PDGF-BB” PMID 25689258 ↗ Feb 2015 |